Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes
Within the limitations of this nationwide study and the available data, sustained GLP-1 RA therapy provided superior glycemic control and was associated with a modest mortality benefit compared with DPP-4i therapy.
Authors
- Marcus Lind (ORCID: https://orcid.org/0000-0003-4423-4135)
- Kathrine Kold Sørensen (ORCID: https://orcid.org/0000-0002-9402-1317)
- Bochra Zareini (ORCID: https://orcid.org/0000-0002-3891-5957)
- Anders Munch (ORCID: https://orcid.org/0000-0003-4625-1465)
- Mikkel Porsborg Andersen (ORCID: https://orcid.org/0000-0001-6162-5205)
- Henrik Imberg (ORCID: https://orcid.org/0000-0001-9447-663X)
- Puriya Daniel Würtz Yazdanfard (ORCID: https://orcid.org/0000-0003-3060-7439)
- Johan Sebastian Ohlendorff
- Sara Hallström (ORCID: https://orcid.org/0000-0002-1119-5267)
- Christian Tobias Torp-Pedersen (ORCID: https://orcid.org/0000-0003-2892-6131)
- Hannah Karin Wood-Kurland
- Ulrik Pedersen-Bjergaard
- Stefanie Lanzinger
- Jens Michelsen
- Thomas Alexander Gerds
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Universität Ulm (DE)
- Region Zealand (DK)
- Sahlgrenska University Hospital (SE)
- Copenhagen University Hospital (DK)
- Zealand University Hospital (DK)
- Zimmer Biomet (Germany) (DE)
- NU Hospital Group (SE)
- Uddevalla sjukhus (SE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Gothenburg (SE)
- Aalborg University (DK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1111/dom.70581
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00